172 related articles for article (PubMed ID: 16850020)
1. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1.
Hoppe B; Beck B; Gatter N; von Unruh G; Tischer A; Hesse A; Laube N; Kaul P; Sidhu H
Kidney Int; 2006 Oct; 70(7):1305-11. PubMed ID: 16850020
[TBL] [Abstract][Full Text] [Related]
2. Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
Michael M; Groothoff JW; Shasha-Lavsky H; Lieske JC; Frishberg Y; Simkova E; Sellier-Leclerc AL; Devresse A; Guebre-Egziabher F; Bakkaloglu SA; Mourani C; Saqan R; Singer R; Willey R; Habtemariam B; Gansner JM; Bhan I; McGregor T; Magen D
Am J Kidney Dis; 2023 Feb; 81(2):145-155.e1. PubMed ID: 35843439
[TBL] [Abstract][Full Text] [Related]
3. The Presence of Oxalobacter formigenes in the Microbiome of Healthy Young Adults.
Barnett C; Nazzal L; Goldfarb DS; Blaser MJ
J Urol; 2016 Feb; 195(2):499-506. PubMed ID: 26292041
[TBL] [Abstract][Full Text] [Related]
4. Is withdrawal of nocturnal hyperhydration possible in children with primary hyperoxaluria treated with RNAi?
Biebuyck N; Destombes C; Prakash R; Boyer O
J Nephrol; 2023 Jun; 36(5):1473-1476. PubMed ID: 37209362
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effects of probiotics and herbal medications on oxalate nephrolithiasis: a mini systematic review.
Taheri H; Feizabadi MM; Keikha R; Afkari R
Iran J Microbiol; 2024 Feb; 16(1):4-18. PubMed ID: 38682062
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic insufficiency as a complication of type 1 diabetes causing enteric hyperoxaluria in a transplant kidney.
Chambers J; Appleton A; Dudley C
BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35787489
[TBL] [Abstract][Full Text] [Related]
7. Lumasiran treatment in pediatric patients with PH1: real-world data within a compassionate use program in Italy.
Taroni F; Peruzzi L; Longo G; Becherucci F; Malgieri G; D'Alessandro MM; Montini G
Clin Kidney J; 2024 May; 17(5):sfae090. PubMed ID: 38742209
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous Liver Kidney Transplantation in a Primary Type 2 Hyperoxaluria With Corrected TOF and Severe Cardiomyopathy: A Case Report.
Subramanian N; Yadav A; Kumar JS; Abraham GP
J Clin Exp Hepatol; 2024; 14(5):101425. PubMed ID: 38721383
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria.
Hoppe B; Groothoff JW; Hulton SA; Cochat P; Niaudet P; Kemper MJ; Deschênes G; Unwin R; Milliner D
Nephrol Dial Transplant; 2011 Nov; 26(11):3609-15. PubMed ID: 21460356
[TBL] [Abstract][Full Text] [Related]
10. A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.
Hoppe B; Niaudet P; Salomon R; Harambat J; Hulton SA; Van't Hoff W; Moochhala SH; Deschênes G; Lindner E; Sjögren A; Cochat P
Pediatr Nephrol; 2017 May; 32(5):781-790. PubMed ID: 27924398
[TBL] [Abstract][Full Text] [Related]
11. The role of Oxalobacter formigenes colonization in calcium oxalate stone disease.
Siener R; Bangen U; Sidhu H; Hönow R; von Unruh G; Hesse A
Kidney Int; 2013 Jun; 83(6):1144-9. PubMed ID: 23536130
[TBL] [Abstract][Full Text] [Related]
12. Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?
Peck AB; Canales BK; Nguyen CQ
Urolithiasis; 2016 Feb; 44(1):45-50. PubMed ID: 26645869
[TBL] [Abstract][Full Text] [Related]
13. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones.
Kaufman DW; Kelly JP; Curhan GC; Anderson TE; Dretler SP; Preminger GM; Cave DR
J Am Soc Nephrol; 2008 Jun; 19(6):1197-203. PubMed ID: 18322162
[TBL] [Abstract][Full Text] [Related]
14. Dietary hyperoxaluria is not reduced by treatment with lactic acid bacteria.
Siener R; Bade DJ; Hesse A; Hoppe B
J Transl Med; 2013 Dec; 11():306. PubMed ID: 24330782
[TBL] [Abstract][Full Text] [Related]
15. Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment.
Cochat P; Hulton SA; Acquaviva C; Danpure CJ; Daudon M; De Marchi M; Fargue S; Groothoff J; Harambat J; Hoppe B; Jamieson NV; Kemper MJ; Mandrile G; Marangella M; Picca S; Rumsby G; Salido E; Straub M; van Woerden CS;
Nephrol Dial Transplant; 2012 May; 27(5):1729-36. PubMed ID: 22547750
[TBL] [Abstract][Full Text] [Related]
16. Oxalobacter formigenes gen. nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract.
Allison MJ; Dawson KA; Mayberry WR; Foss JG
Arch Microbiol; 1985 Feb; 141(1):1-7. PubMed ID: 3994481
[TBL] [Abstract][Full Text] [Related]
17. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada.
Ranganathan N; Friedman EA; Tam P; Rao V; Ranganathan P; Dheer R
Curr Med Res Opin; 2009 Aug; 25(8):1919-30. PubMed ID: 19558344
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis.
Hida M; Aiba Y; Sawamura S; Suzuki N; Satoh T; Koga Y
Nephron; 1996; 74(2):349-55. PubMed ID: 8893154
[TBL] [Abstract][Full Text] [Related]
19. Nephropathy in dietary hyperoxaluria: A potentially preventable acute or chronic kidney disease.
Glew RH; Sun Y; Horowitz BL; Konstantinov KN; Barry M; Fair JR; Massie L; Tzamaloukas AH
World J Nephrol; 2014 Nov; 3(4):122-42. PubMed ID: 25374807
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Lactobacillus plantarum expressing and secreting heterologous oxalate decarboxylase prevents renal calcium oxalate stone deposition in experimental rats.
Sasikumar P; Gomathi S; Anbazhagan K; Abhishek A; Paul E; Vasudevan V; Sasikumar S; Selvam GS
J Biomed Sci; 2014 Aug; 21(1):86. PubMed ID: 25175550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
